Plant Name: Chromolaena odorata
Taxonomic Information:
Plant ID: NPO15117
Plant Latin Name: Chromolaena odorata
Taxonomy Genus: Chromolaena
Taxonomy Family: Asteraceae
Plant External Links:
NCBI TaxonomyDB:
103745
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Ghana; Thailand; Nigeria; IndiaTraditional Medicine System:
Indian FolkGeographical Distribution:
Ghana; Thailand; Nigeria; India
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| FFAR1; FFAR4; | |
| ACHE; | |
| FLT3; CSNK2A1; | |
| CA12; CA9; CA7; CA4; | |
| PPARA; | |
| THRB; | |
| ESR2; | |
| HSD17B1; ALOX15; NOX4; ALDH1A1; | |
| MMP12; | |
| HIF1A; | |
| ABCB1; | |
| SLCO1B1; | |
| LMNA; FABP3; FABP5; THPO; FABP4; APP; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Nuclear hormone receptor subfamily 1 group A | THRB | Thyroid hormone receptor beta-1 | P10828 | CHEMBL1947 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 7.316E-09 | 2.655E-05 | CA12, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 8.862E-09 | 2.757E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.704E-08 | 1.024E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 9.281E-08 | 1.684E-04 | FABP3, FABP4, FABP5, FFAR4 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.084E-07 | 3.731E-04 | CA12, CA4, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.457E-07 | 4.853E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 7.044E-07 | 6.651E-04 | CA12, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.748E-06 | 1.228E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.881E-06 | 2.657E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 5.229E-06 | 2.777E-03 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 6.486E-06 | 3.249E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 6.998E-06 | 3.312E-03 | CA9, CSNK2A1, CYP1A2, FABP3, FFAR4, FLT3, PPARA, TSHR |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 8.405E-06 | 3.735E-03 | FABP3, FABP4, FABP5 |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 1.004E-05 | 4.134E-03 | ACHE, ALDH1A1, HSD17B1, THRB |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 1.436E-05 | 5.573E-03 | ALOX15, APP, FFAR4, NOX4, THPO |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.493E-05 | 5.604E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008283; cell proliferation | GO:0042127; regulation of cell proliferation | 2.706E-05 | 8.418E-03 | APP, CSNK2A1, CYP1B1, FABP3, FLT3, HIF1A, LMNA, MMP12, NOX4, THPO, TSHR |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.168E-05 | 9.715E-03 | CA12, CA4, CA7, CA9, ESR2, MMP12, PPARA, THRB |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.758E-08 | 8.136E-07 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.108E-08 | 6.537E-07 | CA12, CA4, CA7, CA9 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.035E-06 | 2.035E-05 | HSD17B1, CYP1A1, CYP1B1, CYP19A1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 3.805E-06 | 5.612E-05 | FABP3, FABP4, FABP5, PPARA |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 3.204E-05 | 3.781E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.380E-04 | 1.357E-03 | CYP1A2, ALDH1A1, CYP1A1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.949E-04 | 1.642E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 2.748E-04 | 2.027E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 9.197E-04 | 6.029E-03 | CYP1A2, ALOX15 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | ABCB1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypothyroidism | E03 | THRB; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT3; HIF1A; ABCB1; CA9; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP; |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; CYP19A1; CA9; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | ABCB1; |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1; |
| C00-D49: Neoplasms | Glioma | C71 | APP; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| NA: NA | GIST | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| NA: NA | Geographic retinal atrophy | NA | APP; |
| C00-D49: Neoplasms | AML | NA | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; APP; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | THRB; |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | THRB; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperthyroidism | E05 | THRB; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Wound healing | T14.0-T14.1 | THRB; |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; FLT3; ACHE; HIF1A; ABCB1; APP; CA9; |
| E00-E89: Endocrine, nutritional and metabolic diseases | High cholesterol levels in blood | E78.0 | THRB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
